logo-loader
viewPrescient Therapeutics Ltd

Prescient Therapeutics has path forward as they look to future of cancer treatments

Prescient Therapeutics (ASX: PTX) CEO and Managing Director Steven Yatomi-Clarke joined Steve Darling from Proactive to share details about the company that is personalizing cancer treatment using CAR-T cell therapy.

Yatomi -Clarke telling Proactive about their work and also some recent big news for the company including being issued two U.S. patents.

Quick facts: Prescient Therapeutics Ltd

Price: 0.057 AUD

ASX:PTX
Market: ASX
Market Cap: $22.47 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Nexus Minerals launches feasibility study on Pinnacles project and looks...

Nexus Minerals Ltd's (ASX:NXM) Andy Tudor speaks to Proactive's Andrew Scott after announcing they've kicked off a feasibility study on the Pinnacles joint venture (JV) project. The study comes on the back of positive results from an independent scoping study which paves the way for the project...

14 hours, 24 minutes ago

2 min read